Precision oncology knowledge bases currently provide cancer clinicians with a point-of-care interpretation of the therapeutic actionability of somatic genomic sequencing results. Here, we discuss key deficiencies in these knowledge bases that present as opportunities for the next generation of data annotation.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Suehnholz, S. P. et al. Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov. 14, 49–65 (2024).
Yin, X.-J., Wang, R., Shen, H.-S., Jin, J. & Zhu, H.-H. At what point are long-term (>5 years) survivors of APL safe? A study from the SEER database. Cancers 15, 575 (2023).
Church, D. N. et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J. Natl Cancer Inst. 107, 402 (2015).
Arber, D. A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200–1228 (2022).
Schrader, K. A. et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2, 104–111 (2016).
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
Mandelker, D. et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann. Oncol. 30, 1221–1231 (2019).
Stadler, Z. K. et al. Therapeutic implications of germline testing in patients with advanced cancers. J. Clin. Oncol. 39, 2698–2709 (2021).
Tang, X., Berger, M. F. & Solit, D. B. Precision oncology: current and future platforms for treatment selection. Trends Cancer 10, 781–791 (2024).
Chen, A. et al. Tumor genomic profiling practices and perceptions: a survey of physicians participating in the NCI-MATCH trial. JCO Precis. Oncol. https://doi.org/10.1200/PO.20.00217 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Related links
ClinVar: https://www.ncbi.nlm.nih.gov/clinvar/
WHO Classification of Tumours online: https://tumourclassification.iarc.who.int/welcome/
Rights and permissions
About this article
Cite this article
Suehnholz, S., Chakravarty, D. Expanding the utility of precision oncology knowledge bases. Nat Rev Cancer 25, 651–652 (2025). https://doi.org/10.1038/s41568-025-00846-3
Published:
Issue date:
DOI: https://doi.org/10.1038/s41568-025-00846-3
